Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Immunocore Holdings plcNASDAQ: IMCR

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense dips below year-ago levels

Q1 FY2026 income tax expense of $300.5K fell 71.7% year over year, behind the +1059.7% change in trailing-twelve-month income tax expense. Sequentially, it fell 97.2% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.

Context

  • Income tax expense amounted to 4.1% of revenue in FY2025, up 3.5 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -71.7% toward the trailing-twelve-month pace of +1059.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$300.5K-97.2% QoQ
Last fiscal yearDec 2025
$12.21M+925.6% YoY
LTMMar 2026
$11M+1059.7% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-71.7%——
1 year+925.6%——
3-year CAGR+8.2%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

Mixed currencies · from the income statement

Latest · FY2025
12.21M USD
Year-over-year change
+925.6%

Income Tax Expense vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1059.7% is the highest of 7, against a peer median of -99.7%.
  • Income tax expense amounts to 2.9% of revenue for IMCR, versus a peer median of 0.1%.
IMCR Competitors
Income Tax Expense for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€55.58M EUR+228.1%-71.4%2.1%
IMCRImmunocore Holdings plcLTM Mar 2026$11M USD+1059.7%+8.2%2.9%
XNCRXencor, Inc.LTM Jun 2026$2.48M USD+53.2%+55.0%2.4%
CGENCompugen Ltd.LTM Mar 2026$28K USD-99.4%-2.4%0.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026$0 USD-100.0%—0.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
IMMPImmutep LimitedFY2025A$0 AUD——0.0%
IBRXImmunityBio, Inc.LTM Sep 2026-$144K USD——0.1%
MGNXMacroGenics, Inc.LTM Mar 2026-$672K USD-171.2%—0.4%
IMTXImmatics N.V.LTM Mar 2026-€942K EUR-124.8%—2.5%
Peer median (excluding IMCR) —-99.7%-2.4%0.1%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.